Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Editas Medicine (8EM) Stock Price & Analysis

1 Followers

8EM Stock Chart & Stats

CHF 2.06CHF 0.03(1.38%)
At close: 5:30 PM GMT+1
CHF2.25CHF2.5CHF2.75Jul 2Jul 31
Day’s Range
CHF 2.06 - CHF 2.08
52-Week Range
CHF 1.91 - CHF 3.00
Previous Close
CHF 2.03
Volume
N/A
Average Volume (3M)
0
Market Cap
CHF 323.51M
Enterprise Value
CHF 246.12M
Total Cash (Recent Filing)
CHF 190.20M
Total Debt (Recent Filing)
CHF 13.94M
Price to Earnings (P/E)
―
Beta
0.83
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Pipeline Advancement

Regulatory approval moves EDIT-401 from development planning into human testing, creating a defined clinical path for Editas’s cardiovascular gene-editing program. Planned safety and efficacy readouts can provide meaningful validation milestones and clarify the therapy’s longer-term commercial potential.

Manageable Leverage

Lower debt relative to equity gives Editas more financial flexibility than during the 2025 leverage spike. Although the company remains unprofitable, manageable leverage can reduce balance-sheet pressure and leave greater capacity to fund clinical development or respond to financing needs.

Improving Cost Discipline

Falling research and administrative spending, together with smaller recent losses, indicates some progress in controlling the cost base. This does not establish profitability, but it can slow cash consumption and extend the company’s ability to advance its pipeline with available resources.

Bears Say

Persistent Cash Burn

Sustained negative operating and free cash flow means Editas is not yet funding its activities internally. Continued clinical investment therefore depends on existing reserves or external capital, creating financing risk and potentially limiting development flexibility if funding becomes less available.

Deep Operating Losses

Persistent operating and net losses show that Editas has not established sustainable earnings power while advancing its clinical programs. Ongoing losses can consume capital, weaken financial resilience, and make future progress increasingly dependent on successful development or additional funding.

Revenue Volatility

The uneven revenue pattern suggests that collaboration, licensing, or milestone-related income is not yet a consistent growth engine. Without recurring product sales, fluctuations in partnership-related revenue can make planning less predictable and provide limited support for ongoing operating needs.

Editas Medicine News

8EM FAQ

What was Editas Medicine’s price range in the past 12 months?
Editas Medicine lowest stock price was CHF1.91 and its highest was CHF3.00 in the past 12 months.
What is Editas Medicine’s market cap?
Editas Medicine’s market cap is CHF323.51M.
When is Editas Medicine’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Editas Medicine’s earnings last quarter?
Editas Medicine released its earnings results on Nov 09, 2026. The company reported -CHF0.123 earnings per share for the quarter, beating the consensus estimate of -CHF0.152 by CHF0.029.
Is Editas Medicine overvalued?
According to Wall Street analysts Editas Medicine’s price is currently Undervalued.
Does Editas Medicine pay dividends?
Editas Medicine does not currently pay dividends.
What is Editas Medicine’s EPS estimate?
Editas Medicine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Editas Medicine have?
Editas Medicine has 153,580,030 shares outstanding.
What happened to Editas Medicine’s price movement after its last earnings report?
Editas Medicine reported an EPS of -CHF0.123 in its last earnings report, beating expectations of -CHF0.152. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Editas Medicine?
Hedge funds hold Editas Medicine shares: the largest hedge-fund position in Editas Medicine is 583,313,238 shares, and hedge funds increased their holdings by 12.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology